Protect Your Returns With These Three Dividend Kings! Looking for long-term income and stability? Here's 3 dividend kings you won't want to miss! Barchart · Sep 28, 2023
3 Healthcare Stocks to Buy Today The POWR Ratings system points the way to 3 of the most attractive healthcare stocks on the market today. Read on below for why you should consider adding these 3 stocks to your portfolio: Johnson & Johnson (JNJ), Amgen (AMGN) and AbbVie (ABBV). StockNews.com · Sep 18, 2023
Which of these 3 Pharma Stocks Should You Buy, Hold or Sell? The pharmaceutical industry is well-positioned for long-term growth thanks to rising investments in drug development and technological advancements. So, let's analyze whether Johnson & Johnson (JNJ), Calliditas Therapeutics AB (CALT), and Aurora Cannabis (ACB) are a Buy, Hold, or Sell. StockNews.com · Sep 15, 2023
3 Pharma Stocks Surpassing Johnson & Johnson (JNJ) The pharmaceutical sector is anticipated to thrive as demand grows and technology advances. While Johnson & Johnson (JNJ) receives much attention from investors, I believe Horizon Therapeutics Public Limited (HZNP), Dr. Reddy’s Laboratories (RDY), and Novartis (NVS) are better investments right now. Read on. StockNews.com · Sep 12, 2023
Unusual Options Activity in Johnson & Johnson Post Its Kenvue Spinoff Highlights Its Value An unusual number of out-of-the-money put options in Johnson & Johnson come after the Aug. 30 spinoff of its consumer Kenvue business. This could be a good income play for short-put traders. Barchart · Sep 6, 2023
3 Pharma Stocks to Consider Prescribing to for Quality The pharmaceutical industry is expected to thrive amid robust demand and technological advancements. Given the solid long-term prospects of the industry, investors should consider buying quality stocks, Johnson & Johnson (JNJ), AstraZeneca (AZN), and Dr. Reddy’s Laboratories (RDY). Read on. StockNews.com · Sep 4, 2023
Is Johnson & Johnson (JNJ) a Buy Before September Begins? Pharma giant Johnson & Johnson (JNJ) has posted robust second-quarter results and raised its full-year outlook. Should investors look into the stock before September begins? Let’s look at its financial metrics to gauge its prospects…. StockNews.com · Aug 28, 2023
3 Pharma Stocks With Promising Pipelines The pharma industry is anticipated to stay buoyed in the years to come with consistent medical breakthroughs and rising need to serve an aging population. Therefore, pharma stocks Johnson & Johnson (JNJ), Novartis AG (NVS), and Dr. Reddy's Laboratories (RDY), which possess promising pipelines, could be wise portfolio additions now.… StockNews.com · Aug 25, 2023
3 Dividend Kings To Buy And Hold Forever in a Retirement Portfolio Looking for ideas in your financial freedom or retirement portfolio? Here's 3 stocks that fit the bill. Barchart · Aug 17, 2023
3 Pharma Stock Buys You Don’t Want to Miss The pharmaceutical industry is growing amid robust demand. Also, given that healthcare stocks are generally thought of as defensive investments, fundamentally strong Johnson & Johnson (JNJ), Novo Nordisk (NVO), and AstraZeneca (AZN) might be profitable buys now. Read on. StockNews.com · Aug 7, 2023
2 Must-Have Pharma Stocks to Buy in August, 1 to Sell The pharmaceutical industry is poised to thrive amid increasing global healthcare demand. Hence, two quality pharma stocks, Johnson & Johnson (JNJ) and Novartis AG (NVS), could be solid portfolio additions. However, avoiding fundamentally weak stock SNDL Inc. (SNDL) could be a wise choice. Read more. StockNews.com · Aug 3, 2023
Is Johnson & Johnson (JNJ) a Must-Buy Stability Stock? Thanks to the company’s solid first-quarter performance and growing pharmaceutical demand, Johnson & Johnson’s (JNJ) long-term prospects look bright. However, could the company ensure stability for investors amid the current market volatility? Keep reading…. StockNews.com · Aug 1, 2023
Top 3 Pharma Stocks You Can’t Miss out On The ever-transforming pharmaceuticals sector is ready to seize the opportunity to address the growing demand for healthcare across the globe. Therefore, adding these three quality pharma stocks, Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), and Dr. Reddy's Laboratories (RDY), to your portfolio could prove to be beneficial. Read… StockNews.com · Jul 27, 2023
Which Pharma Stock Is the Better July Pick: Johnson & Johnson (JNJ) or Curaleaf Holdings (CURLF)? On the backs of increasing medical requirements amid the soaring incidence of chronic diseases, the pharmaceutical industry’s outlook radiates promise. Given this backdrop, let us compare pharma stocks Johnson & Johnson (JNJ) and Curaleaf Holdings (CURLF) to discover which one of these could be worth buying in July. Read on…. StockNews.com · Jul 3, 2023
StockNews.com · Jun 8, 2023 3 Medical Stock Picks for Investors As the demand for healthcare products and solutions continues to rise, the medical industry is poised for remarkable growth. Therefore, quality medical stocks Johnson & Johnson (JNJ), AstraZeneca (AZN), and Astellas Pharma (ALPMY) could be the ideal investments for your portfolio amid current market uncertainties. Read on….
Barchart · Jun 6, 2023 3 Dividend Kings to Buy if Times Get Tough The United States has yet to enter a recession, but even if we continue in this downturn or come out of it, these three Dividend Kings are top performers to consider.
StockNews.com · May 22, 2023 Johnson & Johnson (JNJ) and SNDL Inc. (SNDL) -- Buy or Sell? Investing in healthcare stocks could help hedge against economic downturns. Thus, Johnson & Johnson (JNJ) could be worth buying. However, I think SNDL (SNDL) is best avoided considering its weak fundamentals. Read on.
Kiplinger · May 4, 2023 Johnson & Johnson Spins Off Kenvue in Biggest IPO Haul Since 2021 Johnson & Johnson rips off Band-Aid and spits out Listerine in a bid to boost margins.
Barchart · May 2, 2023 The Fed Is About To Raise Rates! Get Ready To Plan Your Next Move! Here Are 2 Ideas Depending on How the Next Fed Announcement Goes.
StockNews.com · Apr 5, 2023 Investors Are Keeping This Healthcare Stock Long-Term Despite an uncertain macro environment, healthcare giant Johnson & Johnson (JNJ) reported outstanding results in 2022, reflecting its business segments' continued strength. Moreover, the company has a history of increasing dividends for 60 consecutive years. Given its sustained business momentum and steady dividend payments, investors seem to stay committed to…
Barchart · Apr 5, 2023 Here's 3 Dividend Companies That Just Crossed Above Their 50 Moving Average Trading Smarter, Not Harder With the 50-Day Moving Average Strategy
StockNews.com · Mar 24, 2023 3 Popular Large-Cap Stocks to Buy Right Now As investors continue to digest the news of the recent bank collapses and the Federal Reserve’s quarter-percentage-point rate hike, the stock market outlook seems bumpy for some time. With speculations of an economic slowdown, investing in prominent large-cap stocks Johnson & Johnson (JNJ), Visa (V), and Merck & Co. (MRK)…
StockNews.com · Mar 24, 2023 3 Large-Cap Pharma Stocks to Protect Your Portfolio Through 2023 The worst banking crisis since 2008 could not stop the Fed from raising the benchmark interest rate. The possibility of further policy tightening and strict lending standards for banks might push the economy into a recession this year. Therefore, investing in large-cap pharma stocks Johnson & Johnson (JNJ), Merck &…
StockNews.com · Mar 24, 2023 4 Best Pharma Stocks to Buy for the Long Haul With the persistent rise in lifestyle diseases, the pharmaceutical industry is well poised for strong growth in the long term. Also, with the Fed likely to keep increasing the interest rates, the economy is likely to enter a recession, making pharma stocks attractive investment options. Therefore, investors could look to…
StockNews.com · Mar 23, 2023 The Strongest Pharma Stock This Week Tighter bank lending and the Fed’s continued fight against inflation will likely push the economy into a recession this year. In this scenario, investors can look to invest in the pharma giant Johnson & Johnson (JNJ), given its financial strength, reliable dividend payments, and solid growth prospects. Read more….